🔗 Share this article

A shadow market for unapproved weight-loss medications is being driven by TikTok fitness influencers and vendors on communication apps, based on new investigations.

Experimental Treatment Gaining Traction Online

The experimental drug, which is still in clinical trials, is being promoted by social media influencers for its supposed weight-reducing properties. Viewers are urged to contact these profiles privately for supplier links, while also receiving promotional offers.

Active Trade on Messaging Platforms

Separately, a robust trade exists on Telegram, where communities with numerous of participants share “before and after” photos, injection guides and assertions of rapid British shipping. Vendors market the drug there before redirecting customers to other platforms for purchases.

Learning About The Experimental Drug

This medication is an experimental injectable developed by US drugmaker Eli Lilly. The drug targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist patients lose up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.

Medical Experts Voice Concerns

Nevertheless, doctors and chemists have warned that the sale of what remains an unlicensed medication in the UK is a cause for concern and could result in individuals administering products of unknown origin.

Several professionals stated the popularity for the experimental drug could be linked to the increasing cost of licensed weight loss treatments such as Mounjaro.

Legal Position and Enforcement

Selling the unapproved drug on TikTok or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be promoted or supplied for personal consumption under the British medical regulations.

Several content creators attempt to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach pharmaceutical, advertising, and customer regulations, potentially leading to fines, prosecution or imprisonment.

Service Reaction and Content Elimination

According to the social media company, the service has removed violative content and banned associated hashtags and query recommendations. The company said it was dedicated to maintaining the platform safe and investing in strengthening compliance measures.

Online Marketplace Operations

Research also discovered communities with up to nine thousand participants marketing the experimental drug using the platform's integrated discovery tool, which operates like a public directory. Typing “retatrutide” immediately displays groups with thousands of users, populated with images of weight loss, glowing reviews and detailed instructions for mixing or injecting at residence.

Within minutes of joining one community, a vendor posted contact information, where most purchases take place. The seller sent an instruction manual and promised delivery within two days. When questioned whether the substance was genuine, one seller responded: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. Not one inquired about weight, medical conditions or past usage.

Product Details and Costs

Within these communities, posts display black plastic packages with Royal Mail labels, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, mixed at home with purified liquid, or pre-filled pens typically sold at £160 for 20mg. When questioned how much time a injector should be used, vendors give contradictory responses varying between a few weeks to “depends on your body”.

Service Moderation and Safety Actions

A spokesperson for the messaging service said it actively monitored dangerous content on its service including material that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“Individuals are administering substances they can’t verify. Although the research behind retatrutide is valid, these digital versions may not contain what they advertise,” stated Jason Murphy, the head of pharmaceutical services at a pharmacy service.

A medical professional of Asda Online Doctor connected the increase in demand to current cost increases for approved slimming drugs such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But fake treatments are highly risky. You cannot know what’s contained or whether the environment they were made in was clean,” she explained.

Her team has already seen patients harmed by personal administration from unconfirmed suppliers. “We recognize the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” said the doctor. “These substances could be impure or improperly measured.”

Manufacturer Statement

A spokesperson from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been reviewed or approved by any government authority anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they explained, noting that any product “falsely representing itself as a Lilly investigational substance not yet authorized … may subject patients to potentially significant health risks”.